He has global experience in strategic and operational leadership levels with an extensive track record of leadership and success in building companies, businesses, teams, and brands for over 30 years
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
Itolizumab achieved key secondary endpoint of endoscopic remission of 16.7% compared to 16.7% for adalimumab and 6.7% for placebo
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
Kiran Mazumdar-Shaw received the award from Janak Kumar Mehta, President of ISQ and Chairman & Managing Director, TQM International
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
The celebrations began with the unveiling of the Biocon Anthem
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
Subscribe To Our Newsletter & Stay Updated
